What's new in the treatment of advanced prostate cancer?
Increased insight into the biology of prostate cancer and the emergence of new therapeutic strategies and chemotherapeutic agents has changed approaches in treating patients with advanced prostate cancer. After secondary hormonal manipulations, new approaches include: second-line hormonal therapy, chemotherapy, immunotherapy with granulocyte macrophage-colony stimulating factor (GM-CSF) therapy, dendritic cell therapy, gene vaccination therapy, inhibition and/or blockade of growth factor receptors or growth factor receptor pathways, inhibition of neo-angiogenesis and inhibition of invasion and metastases.
Sternberg
C N
CN
Chief, Department of Medical Oncology, San Camillo-Forlanini Hospital, Vincenzo Pansadoro Foundation, Via Aurelia 559, 00165 Rome, Italy. cstern@mclink.it
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D015316:Genetic Therapy / Q000379:methods; D006131:Growth Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy*; D013467:Sulindac / Q000031:analogs & derivatives / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D004164:Diphosphonates; D006131:Growth Inhibitors; D014807:Vitamin D; D013467:Sulindac; C025463:sulindac sulfone